Accelerating Development of RO-104
Kemwell Biopharma will manufacture RO-104, a novel biologic targeting three key angiogenic pathways (VEGF-A, VEGF-C, Ang-2) linked to nAMD, a leading cause of blindness. RO-104’s ability to bind these targets positions it as a first-in-class monotherapy biologic, set to transform retinal disease treatment.
Leveraging Expertise for Expedited Development
Kemwell, operating India’s first commercial cGMP facility, brings extensive protein manufacturing expertise to the partnership. Combined with RevOpsis’ innovative Rev-Mod platform, this collaboration aims to expedite the development of multispecific biologics.
“Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics,” said Ram Bhandari, MD, Co-founder and Interim CEO of RevOpsis. “Kemwell’s track record in high-quality biologics manufacturing, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies efficiently.”
Anurag Bagaria, CEO of Kemwell Biopharma, added, “We are excited to collaborate with RevOpsis to manufacture and commercialize RO-104. This partnership underscores our commitment to delivering high-quality biologics for patients in need.”
Streamlined Therapeutic Discovery to IND Submission
This alliance provides RevOpsis with a critical solution to transition from pre-clinical activities to first-in-human clinical trials, expediting RO-104 and the broader platform development. Integrating RevOpsis’ multispecific biologics platform with Kemwell’s manufacturing expertise aims to streamline therapeutic discovery to IND submission timelines.
About RO-104
RO-104, leveraging the Rev-Mod platform, is RevOpsis’ lead candidate. It addresses three key angiogenic pathways (VEGF-A, VEGF-C, Ang-2) in retinal vascular disease progression, including nAMD, representing a significant advancement in treatment supported by preclinical evidence.
About Rev-Mod Platform
The Rev-Mod Platform employs a ‘plug-and-play’ approach to expedite the discovery and development of multispecific biologics for prevalent chronic diseases. It features a library of 30 billion fully human antibody components, enabling rapid identification and assembly of multispecific candidates.
About RevOpsis Therapeutics
Founded in 2018, RevOpsis Therapeutics is a biopharmaceutical company focused on ophthalmic therapies. Leveraging its proprietary Rev-Mod Platform, RevOpsis aims to develop groundbreaking treatments for chronic diseases.
About Kemwell Biopharma
Kemwell Biopharma is a leading CDMO providing development and manufacturing services for therapeutic proteins. Located in Bangalore, India, Kemwell offers end-to-end services for biopharmaceutical development and manufacturing.
https://finance.yahoo.com/news/revopsis-secures-16-5-million-131500007.html?guccounter=1
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Cartesian Therapeutics Secures $130M in PIPE Financing for Pioneering mRNA Cell Therapy
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company known for its innovative mRNA cell therapies targeting autoimmune diseases, announced today a significant milestone in its financial journey. The company has entered into a securities...
New Era of Genome Engineering: Beyond CRISPR
“Everything in the last 14 years of genome editing has been based on CRISPR. We have been whipping this horse for a decade and a half, but we need more programmable functions with complexity beyond the molecular scissors that cut RNA and DNA,” says Patrick Hsu, PhD,...
When the Wegovy stops, the weight gain restarts. Could a GLP-1 gene therapy change that?
GLP-1 drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy work to address obesity—as long as a patient keeps taking them. Harith Rajagopalan, M.D., Ph.D. thinks his company, Fractyl Health, may have the answer: a gene therapy that integrates a GLP-1-secreting...
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label End-of-Phase II meeting with FDA scheduled for late July to finalize pivotal program design Based on recent commercial...
Related Services
Plasmids GMP Services
AAV GMP Services
